Title: Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by
Multi-Omic data analysis
Version: 1 Date: 13 Apr 2023
Reviewer's report:
PEER REVIEWER ASSESSMENTS:
OBJECTIVE - Full research articles: is there a clear objective that addresses a testable research
question(s) (brief or other article types: is there a clear objective)?
Yes - there is a clear objective
DESIGN - Is the current approach (including controls and analysis protocols) appropriate for
the objective?
Yes - the approach is appropriate
EXECUTION - Are the experiments and analyses performed with technical rigor to allow
confidence in the results?
Yes - experiments and analyses were performed appropriately
STATISTICS - Is the use of statistics in the manuscript appropriate?
Yes - appropriate statistical analyses have been used in the study
INTERPRETATION - Is the current interpretation/discussion of the results reasonable and not
overstated?
No - there are minor issues
OVERALL MANUSCRIPT POTENTIAL - Is the current version of this work technically
sound? If not, can revisions be made to make the work technically sound?
Maybe - with major revisions
PEER REVIEWER COMMENTS:
GENERAL COMMENTS: The authors aim to show prognostic role of OSBPL3 and look
for the functionality of this gene. OSBPL3 is one of the potential drivers of MAPK/AKT
pathway and highly expressed in solid tumors. #t is related with poor prognosis in different
types of solid tumors. The authors selected CRC to show the prognostic role. They included
all stages of cancer noted major clinicopathological characteristics. However, they did not take
homogeneous stage, not noted surgery, right or left side colonic tumor, RAS and BRAF mutation
and MSI status. They outlined molecular pathways and the potential role of OSBPL3.  When
whole group analyzed, they clearly showed significant prognostic role of OSBPL3 in CRC.
In the context of oncology clinical practice, OSBPL3 must be analyzed in homogeneous stage
(You could not include stage I and 4 diseases together), and the study must include molecular
prognostic biomarkers like KRAS, BRAF, MSI, cerbb2 and treatment characteristics of the
patients. Therefore, this study produces theoretical  knowledge, but did not produce clinically
important data.
REQUESTED REVISIONS:
They have to exclude drug information, because these drugs are not used to treat CRC patients,
so any oncologist could use OSBPL3 for these drugs. Low clinical value and decrease the total
worth of the study.  Also they stated that IO agents and relation with OSBPL3 expression but
they did not include any patients treated with IO agents. They have to clear the sentences that
overstatement for the goal of this study.
ADDITIONAL REQUESTS/SUGGESTIONS:
They have to include strategies ( surgery, and chemotherapy) , patients characteristics ( right
and left colon, rectum cancer), and molecular test result KRAS, BRAF and MSI.
Title: Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by
Multi-Omic data analysis
Version: 1 Date: 13 Apr 2023
Reviewer's report:
PEER REVIEWER ASSESSMENTS:
OBJECTIVE - Full research articles: is there a clear objective that addresses a testable research
question(s) (brief or other article types: is there a clear objective)?
Yes - there is a clear objective
DESIGN - Is the current approach (including controls and analysis protocols) appropriate for
the objective?
Yes - the approach is appropriate
EXECUTION - Are the experiments and analyses performed with technical rigor to allow
confidence in the results?
Yes - experiments and analyses were performed appropriately
STATISTICS - Is the use of statistics in the manuscript appropriate?
Yes - appropriate statistical analyses have been used in the study
INTERPRETATION - Is the current interpretation/discussion of the results reasonable and not
overstated?
No - there are minor issues
OVERALL MANUSCRIPT POTENTIAL - Is the current version of this work technically
sound? If not, can revisions be made to make the work technically sound?
Maybe - with major revisions
PEER REVIEWER COMMENTS:
GENERAL COMMENTS: The authors aim to show prognostic role of OSBPL3 and look
for the functionality of this gene. OSBPL3 is one of the potential drivers of MAPK/AKT
pathway and highly expressed in solid tumors. #t is related with poor prognosis in different
types of solid tumors. The authors selected CRC to show the prognostic role. They included
all stages of cancer noted major clinicopathological characteristics. However, they did not take
homogeneous stage, not noted surgery, right or left side colonic tumor, RAS and BRAF mutation
and MSI status. They outlined molecular pathways and the potential role of OSBPL3.  When
whole group analyzed, they clearly showed significant prognostic role of OSBPL3 in CRC.
In the context of oncology clinical practice, OSBPL3 must be analyzed in homogeneous stage
(You could not include stage I and 4 diseases together), and the study must include molecular
prognostic biomarkers like KRAS, BRAF, MSI, cerbb2 and treatment characteristics of the
patients. Therefore, this study produces theoretical  knowledge, but did not produce clinically
important data.
REQUESTED REVISIONS:
They have to exclude drug information, because these drugs are not used to treat CRC patients,
so any oncologist could use OSBPL3 for these drugs. Low clinical value and decrease the total
worth of the study.  Also they stated that IO agents and relation with OSBPL3 expression but
they did not include any patients treated with IO agents. They have to clear the sentences that
overstatement for the goal of this study.
ADDITIONAL REQUESTS/SUGGESTIONS:
They have to include strategies ( surgery, and chemotherapy) , patients characteristics ( right
and left colon, rectum cancer), and molecular test result KRAS, BRAF and MSI.
Please review this paper.
user
Title: Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by
Multi-Omic data analysis
Version: 1 Date: 13 Apr 2023
Reviewer's report:
PEER REVIEWER ASSESSMENTS:
OBJECTIVE - Full research articles: is there a clear objective that addresses a testable research
question(s) (brief or other article types: is there a clear objective)?
Yes - there is a clear objective
DESIGN - Is the current approach (including controls and analysis protocols) appropriate for
the objective?
Yes - the approach is appropriate
EXECUTION - Are the experiments and analyses performed with technical rigor to allow
confidence in the results?
Yes - experiments and analyses were performed appropriately
STATISTICS - Is the use of statistics in the manuscript appropriate?
Yes - appropriate statistical analyses have been used in the study
INTERPRETATION - Is the current interpretation/discussion of the results reasonable and not
overstated?
No - there are minor issues
OVERALL MANUSCRIPT POTENTIAL - Is the current version of this work technically
sound? If not, can revisions be made to make the work technically sound?
Maybe - with major revisions
PEER REVIEWER COMMENTS:
GENERAL COMMENTS: The authors aim to show prognostic role of OSBPL3 and look
for the functionality of this gene. OSBPL3 is one of the potential drivers of MAPK/AKT
pathway and highly expressed in solid tumors. #t is related with poor prognosis in different
types of solid tumors. The authors selected CRC to show the prognostic role. They included
all stages of cancer noted major clinicopathological characteristics. However, they did not take
homogeneous stage, not noted surgery, right or left side colonic tumor, RAS and BRAF mutation
and MSI status. They outlined molecular pathways and the potential role of OSBPL3.  When
whole group analyzed, they clearly showed significant prognostic role of OSBPL3 in CRC.
In the context of oncology clinical practice, OSBPL3 must be analyzed in homogeneous stage
(You could not include stage I and 4 diseases together), and the study must include molecular
prognostic biomarkers like KRAS, BRAF, MSI, cerbb2 and treatment characteristics of the
patients. Therefore, this study produces theoretical  knowledge, but did not produce clinically
important data.
REQUESTED REVISIONS:
They have to exclude drug information, because these drugs are not used to treat CRC patients,
so any oncologist could use OSBPL3 for these drugs. Low clinical value and decrease the total
worth of the study.  Also they stated that IO agents and relation with OSBPL3 expression but
they did not include any patients treated with IO agents. They have to clear the sentences that
overstatement for the goal of this study.
ADDITIONAL REQUESTS/SUGGESTIONS:
They have to include strategies ( surgery, and chemotherapy) , patients characteristics ( right
and left colon, rectum cancer), and molecular test result KRAS, BRAF and MSI.
assistant